Cargando…
Long-Term Outcomes of Tuberous Sclerosis Complex-Associated Non-functional Pancreatic Neuroendocrine Tumors: Should We Be More Conservative?
BACKGROUND: Hereditary syndromes such as tuberous sclerosis complex (TSC) account for 10% of pancreatic neuroendocrine tumors (PNETs). Surgical intervention is the current standard of care for sporadic PNETs (spPNETs) that are >2 cm in size. We compared the long-term outcomes of resected TSC-PNET...
Autores principales: | Arya, Shahrzad, Ventin, Marco, Nebbia, Martina, Fernandez-del Castillo, Carlos, Lionetto, Gabriella, Qadan, Motaz, Lillemoe, Keith D., Deshpande, Vikram, Catalano, Onofrio A., Thiele, Elizabeth A., Ferrone, Cristina R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10562497/ https://www.ncbi.nlm.nih.gov/pubmed/37648887 http://dx.doi.org/10.1245/s10434-023-14157-0 |
Ejemplares similares
-
Recurrence of Pancreatic Neuroendocrine Tumors and Survival Predicted by Ki67
por: Genç, C. G., et al.
Publicado: (2018) -
Importance of Nodal Metastases Location in Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma: Results from a Prospective, Lymphadenectomy Protocol
por: Malleo, Giuseppe, et al.
Publicado: (2022) -
What Should Guide the Performance of Venous Resection During Pancreaticoduodenectomy for Pancreatic Ductal Adenocarcinoma with Venous Contact?
por: Navez, Julie, et al.
Publicado: (2021) -
CA19.9 Response and Tumor Size Predict Recurrence Following Post-neoadjuvant Pancreatectomy in Initially Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma
por: Maggino, Laura, et al.
Publicado: (2022) -
Adjuvant Chemoradiation for Pancreatic Adenocarcinoma: The Johns Hopkins Hospital—Mayo Clinic Collaborative Study
por: Hsu, Charles C., et al.
Publicado: (2010)